Regulation of leptin receptor expression in human papillary thyroid cancer cells

Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie
Shih-Ping ChengJie-Jen Lee

Abstract

Epidemiological studies suggest an important link between obesity and thyroid cancer. The adipose tissue-derived polypeptide leptin acting via leptin receptor may modulate cell migration of thyroid cancer cells. Previously we have demonstrated that leptin receptor is overexpressed in papillary thyroid cancer and is associated with tumor aggressiveness. The present study was undertaken to explore the possible regulatory factors which would influence leptin receptor expression in papillary thyroid cancer cells. We found that DNA methyltransferase inhibitor (5-Aza-2'-deoxycytidine) and histone deacetylase inhibitor (trichostatin A) reduced leptin receptor expression. Conversely, insulin upregulated leptin receptor expression in a time- and dose-dependent manner. Hypoxia-mimicking agent (cobalt chloride) had no effect on leptin receptor expression. Taken together, our study provides evidence that epigenetic events and insulin stimulation take part in regulation of leptin receptor expression in papillary thyroid cancer cells.

References

Dec 29, 1995·Cell·L A TartagliaR I Tepper
May 18, 2000·Biochemical and Biophysical Research Communications·M HikitaY Saito
Sep 7, 2002·The Journal of Biological Chemistry·Alexandra GrosfeldMichele Guerre-Millo
May 18, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William Kevin KellyVictoria M Richon
Jul 15, 2005·Seminars in Hematology·Richard L Momparler
Dec 13, 2005·The Biochemical Journal·Gema Frühbeck
Jan 13, 2006·Trends in Biochemical Sciences·Robert J Klose, Adrian P Bird
Feb 21, 2006·Thyroid : Official Journal of the American Thyroid Association·Francisco Alvarez-NuñezUNKNOWN Thyroid Neoplasia Study Group
Mar 15, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Cecilia GarofaloEva Surmacz
Sep 2, 2006·Endocrinology·Mingzhao Xing
Sep 7, 2006·Nature Reviews. Drug Discovery·Jessica E BoldenRicky W Johnstone
Feb 27, 2007·Cell·Peter A Jones, Stephen B Baylin
Aug 30, 2008·The International Journal of Biochemistry & Cell Biology·Rachel CoddAmalie A H Pakchung
Oct 16, 2008·The Journal of Clinical Endocrinology and Metabolism·Jennifer A WoyachManisha H Shah
Sep 17, 2009·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Rob C M van KruijsdijkFrank L J Visseren
Apr 30, 2010·Oncology Reports·Shih-Ping ChengChin-Wen Chi
Sep 10, 2010·Medical Hypotheses·Shih-Ping ChengChien-Liang Liu
Jan 27, 2011·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Cari M KitaharaAmy Berrington de González
Feb 18, 2011·Journal of Molecular Endocrinology·Diego RussoSebastiano Filetti
Mar 1, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Laszlo OtvosEva Surmacz
May 17, 2011·Molecular Carcinogenesis·Paul A CarrollElizabeth M Connolly
Jul 20, 2011·Thyroid : Official Journal of the American Thyroid Association·Briseis Aschebrook-KilfoyMary H Ward
Sep 1, 2011·Nature Reviews. Endocrinology·Yuri E Nikiforov, Marina N Nikiforova

❮ Previous
Next ❯

Citations

Jul 25, 2013·Thyroid : Official Journal of the American Thyroid Association·Theodora Pappa, Maria Alevizaki
Apr 18, 2014·Endocrine-related Cancer·Marjory Alana MarcelloLaura Sterian Ward
Sep 17, 2013·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·K Pazaitou-PanayiotouC S Mantzoros
Jan 21, 2015·Endocrine-related Cancer·Shih-Ping ChengJie-Jen Lee
Jan 21, 2018·Hormones & Cancer·Won Gu Kim, Sheue-Yann Cheng

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cell Migration in Cancer and Metastasis

Migration of cancer cells into surrounding tissue and the vasculature is an initial step in tumor metastasis. Discover the latest research on cell migration in cancer and metastasis here.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.